Gilead Acquires Ouro Medicines for $2.18 Billion to Boost Autoimmune Pipeline
Gilead to acquire Ouro Medicines for $1.675B upfront + $500M milestones, adding clinical-stage BCMAxCD3 therapy gamgertamig for severe autoimmune conditions. Partnership with Galapagos announced.
